|Quantity Discounts||1 - 2|
|3 - 4|
|5 - 6|
|7 - 9|
|10 - 9999|
Choosing the Right Drug Approval Pathway: Speedier Approvals with Less Risk
The 21st Century Cures Act has ushered in a new era of business friendliness. Helped along by a pro-business White House and Congress, the FDA wants to help get your new drugs to market.
This is the moment to discover how, with guidance from a top Washington lawyer.
Julie Tibbets Esq., a partner in the FDA regulatory practice of Alston & Bird, will help you figure out your own fast-track strategies, with specifics including:
Golden opportunities don’t come along every day. For new-drug developers, this is such a moment. Gain the tools to fast-track your innovative therapies ... ahead of the competition.
This presentation is right for clinical-stage drug and biologics developers innovating new therapies, especially for unmet needs and rare diseases. Specific job responsibilities include but are not limited to:
Julie Tibbets Esq., a partner in the FDA regulatory practice of Alston & Bird, works closely with clinical-stage companies on product development and approval strategies, and communicating to investors regarding those pathways.
Copyright ©2018. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing